Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 12, 2001, Pages 3555-3559

  Carter, K C ^a   Mullen, A B ^a   Sundar, S ^a   Kenney, R T ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

STIBOGLUCONATE SODIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIMONY SODIUM GLUCONATE; CRICETINAE; DRUG CARRIERS; FEMALE; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGES; MALE; MESOCRICETUS; MICE; MICE, INBRED BALB C; PARASITE EGG COUNT; SCHISTOSOMICIDES; SURFACE-ACTIVE AGENTS;

EID: 0035192136     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.12.3555-3559.2001     Document Type: Article

References (22)

1. Human leishmaniasis: Clinical, diagnostic and chemotherapeutic developments in the last 10 years
2. Regulation of leishmania populations within the host. I. The variable course of Leishmania donovani infections in mice
3. The therapeutic effect of sodium stibogluconate in the BALB/c mice infected with L. donovani is organ dependent
4. A direct comparison of sodium stibogluconate treatment in two animal models of human visceral leishmaniasis, mouse and hamster
5. Genetic control of drug-induced recovery from murine visceral leishmaniasis
6. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis
7. Visceral leishmaniasis in the BALB/c mouse: Sodium stibogluconate treatment during acute and chronic stages of infection. II. Changes in tissue drug distribution
8. The distribution of free and non-ionic vesicular sodium stibogluconate in the dog
9. Visceral leishmaniasis in clinical practice
10. Gene amplification in Leishmania tarentaole selected for resistance to sodium stibogluconate
11. Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant leishmania
12. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania spp. from patients unresponsive to pentavalent antimony therapy
13. The biological and immunological properties of sand fly saliva and its role in the establishment of Leishmania infections
14. Efflux systems and increased trypanothionine levels in arsenite-resistant Leishmania
15. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani
16. Visceral leishmaniasis in the BALB/c mouse: A comparison of the eficacy of sodium stibogluconate with those of three proprietary formulations of amphotericin B
17. Non-ionic surfactant vesicles for the treatment of visceral leishmaniasis
18. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents
19. In vitro life cycle of pentamidine-resistant amastigotes: Stability of the chemoresistant phenotypes is dependent on the level of resistance induced
20. v reducing activity correlates with antimony susceptibility in Leishmania donovani
21. Comparison of the efficacy of free and non-ionic-surfactant vesicular formulation of paromomycin in a murine model of visceral leishmaniasis
22. Visceral leishmaniasis in the BALB/c mouse: A comparison of the in vivo activity of five non-ionic surfactant vesicle preparations of sodium stibogluconate